Canadian association of gastroenterology clinical practice guidelines: The use of infliximab in Crohn's disease

Canadian Journal of Gastroenterology

Volumn 18, Issue 8, 2004, Pages 503-508

  Panaccione, Remo ^a   Fedorak, Richard Neil ^b   Aumais, Guy ^c   Bernstein, Charles N ^d   Bitton, Alain ^e   Croitoru, Ken ^f   Enns, Robert ^g   Feagan, Brian ^h   Fishman, Marty ^g   Greenberg, Gordon ⁱ   Griffiths, Anne ⁱ   Marshall, John K ^f   Rasul, Imran ^j   Sadowski, Daniel ^b   Seidman, Ernest ^k   Steinhart, Hillary ⁱ   Sutherland, Lloyd ^a   Walli, Eric ^l   Wild, Gary ^e   Williams, C Noel ^b   Zachos, Mary ⁱ   more..

^a UNIVERSITY OF CALGARY   (Canada)

^b UNIVERSITY OF ALBERTA   (Canada)

^c MAISONNEUVE ROSEMONT HOSPITAL   (Canada)

^d UNIVERSITY OF MANITOBA   (Canada)

^e MCGILL UNIVERSITY   (Canada)

^f MCMASTER UNIVERSITY   (Canada)

^g UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^h UNIVERSITY OF WESTERN ONTARIO   (Canada)

ⁱ UNIVERSITY OF TORONTO   (Canada)

^j CREDIT VALLEY HOSPITAL   (Canada)

^k UNIVERSITY OF MONTREAL   (Canada)

^l Winnipeg Clinic   (Canada)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ADRENALIN; AZATHIOPRINE; DIPHENHYDRAMINE; GLUCOCORTICOID; HYDROCORTISONE; HYDROCORTISONE SODIUM SUCCINATE; IMMUNOSUPPRESSIVE AGENT; INFLIXIMAB; MERCAPTOPURINE; METHOTREXATE; OXYGEN; PARACETAMOL;

ARTICLE; CANADA; CLINICAL PRACTICE; CLINICAL STUDY; CLINICAL TRIAL; CORRELATION COEFFICIENT; CROHN DISEASE; DISEASE SEVERITY; DRUG CONTRAINDICATION; DRUG DOSE REGIMEN; DRUG ERUPTION; DRUG HYPERSENSITIVITY; DRUG INDICATION; DRUG SAFETY; DRUG UTILIZATION; EVIDENCE BASED MEDICINE; GASTROENTEROLOGY; HUMAN; INFUSION; INFUSION REACTION; MAINTENANCE DRUG DOSE; MAINTENANCE THERAPY; MEDICAL RESEARCH; MEDICAL SOCIETY; PATIENT MONITORING; POPULATION RESEARCH; PRACTICE GUIDELINE; PRIORITY JOURNAL; PRURITUS; SIDE EFFECT; VALIDATION PROCESS;

EID: 4544362788     PISSN: 08357900     EISSN: None     Source Type: Journal    
DOI: 10.1155/2004/670161     Document Type: Article

References (60)

1. Panaccione R, Fedorak RN, Feagan B. Canadian Association of Gastroenterology Clinical Practice Guidelines: The use of infliximab in Crohn's disease. Can J Gastroenterol 2001;15:367-70.
2. Hanauer SB, Feagan BG, Lichtenstein GR, et al. Maintenance infliximab for Crohn's disease: The ACCENT I randomised trial. Lancet 2002;359:1541-9.
3. Sands BE, Anderson FH, Bernstein CN, et al. Infliximab maintenance therapy for fistulizing Crohn's disease. N Engl J Med 2004;350:876-85.
4. Marshall JK. A critical approach to clinical practice guidelines. Can J Gastroenterol 2000;14:505-9.
5. Targan SR, Hanauer SB, van Deventer SJ, et al. A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. Crohn's Disease cA2 Study Group. N Engl J Med 1997;337:1029-35.
6. Present DH, Rutgeerts P, Targan S, et al. Infliximab for the treatment of fistulas in patients with Crohn's disease. N Engl J Med 1999;340:1398-405.
7. Rutgeerts P, D'Haens G, Targan S, et al. Efficacy and safety of retreatment with anti-tumor necrosis factor antibody (infliximab) to maintain remission in Crohn's disease. Gastroenterol 1999;117:761-9.
8. Stephens MC, Shepanski MA, Mamula P, Markowitz JE, Brown KA, Baldassano RN. Safety and steroid-sparing experience using infliximab for Crohn's disease at a pediatric inflammatory bowel disease center. Am J Gastroenterol 2003;98:104-11.
9. Cezard JP, Nouaili N, Talbotec C, et al. A prospective study of the efficacy and tolerance of a chimeric antibody to tumor necrosis factors (remicade) in severe pediatric crohn disease. J Pediatr Gastroenterol Nutr 2003;36:632-6.
10. Serrano MS, Schmidt-Sommerfeld E, Kilbaugh TJ, Brown RF, Udall JN Jr, Mannick EE. Use of infliximab in pediatric patients with inflammatory bowel disease. Ann Pharmacother 2001;35:823-8.
11. Hyams JS, Markowitz J, Wyllie R. Use of infliximab in the treatment of Crohn's disease in children and adolescents. J Pediatr 2000;137:192-6.
12. Kugathasan S, Werlin SL, Martinez A, Rivera MT, Heikenen JB, Binion DG. Prolonged duration of response to infliximab in early but not late pediatric Crohn's disease. Am J Gastroenterol 2000;95:3189-94.
13. Ardizzone S, Colombo E, Maconi G, et al. Infliximab in treatment of Crohn's disease: The Milan experience. Dig Liver Dis 2002;34:411-8.
14. Hommes DW, van de Heisteeg BH, van der Spek M, Bartelsman JF, van Deventer SJ. Infliximab treatment for Crohn's disease: One-year experience in a Dutch academic hospital. Inflamm Bowel Dis 2002;8:81-6.
15. Panaccione R. Infliximab for the treatment of Crohn's disease: Review and indications for clinical use in Canada. Can J Gastroenterol 2001;15:371-5.
16. Ricart E, Panaccione R, Loftus EV, Tremaine WJ, Sandborn WJ. Infliximab for Crohn's disease in clinical practice at the Mayo Clinic: The first 100 patients. Am J Gastroenterol 2001;96:722-9.
17. Arnott ID, McDonald D, Williams A, Ghosh S. Clinical use of Infliximab in Crohn's disease: The Edinburgh experience. Aliment Pharmacol Ther 2001;15:1639-46.
18. Mortimore M, Gibson PR, Selby WS, Radford-Smith GL, Florin TH. Early Australian experience with infliximab, a chimeric antibody against tumour necrosis factor-alpha, in the treatment of Crohn's disease: Is its efficacy augmented by steroid-sparing immunosuppressive therapy? The Infliximab User Group. Intern Med J 2001;31:146-50.
19. Lionetti P, Bronzini F, Salvestrini C, et al. Response to infliximab is related to disease duration in paediatric Crohn's disease. Aliment Pharmacol Ther 2003;18:425-31.
20. Farrell RJ, Shah SA, Lodhavia PJ, et al. Clinical experience with infliximab therapy in 100 patients with Crohn's disease. Am J Gastroenterol 2000;95:3490-7.
21. Baldassano R, Braegger CP, Escher JC, et al. Infliximab (REMICADE) therapy in the treatment of pediatric Crohn's disease. Am J Gastroenterol 2003;98:833-8.
22. Cohen RD, Tsang JF, Hanauer SB. Infliximab in Crohn's disease: First anniversary clinical experience. Am J Gastroenterol 2000;95:3469-77.
23. Sample C, Bailey RJ, Todoruk D, et al. Clinical experience with infliximab for Crohn's disease: The first 100 patients in Edmonton, Alberta. Can J Gastroenterol 2002;16:165-70.
24. Clark W, Raftery J, Song F, et al. Systematic review and economic evaluation of the effectiveness of infliximab for the treatment of Crohn's disease. Health Technol Assess 2003;7:1-67.
25. Wicks AC, Thomas C, Curran R, Mayberry JF. Infliximab and Crohn's QOL. Aliment Pharmacol Ther 2002;16:1831-2.
26. Van Assche G, Vanbeckevoort D, Bielen D, et al. Magnetic resonance imaging of the effects of infliximab on perianal fistulizing Crohn's disease. Am J Gastroenterol 2003;98:332-9.
27. Agnholt J, Dahlerup JF, Buntzen S, Tottrup A, Nielsen SL, Lundorf E. Response, relapse and mucosal immune regulation after infliximab treatment in fistulating Crohn's disease. Aliment Pharmacol Ther 2003;17:703-10.
28. Sabate JM, Villarejo J, Lemann M, Bonnet J, Allez M, Modigliani R. An open-label study of thalidomide for maintenance therapy in responders to infliximab in chronically active and fistulizing refractory Crohn's disease. Aliment Pharmacol Ther 2002;16:1117-24.
29. Martinez-Borra J, Lopez-Larrea C, Gonzalez S, et al. High serum tumor necrosis factor-alpha levels are associated with lack of response to infliximab in fistulizing Crohn's disease. Am J Gastroenterol 2002;97:2350-6.
30. Regueiro M, Mardini H. Treatment of perianal fistulizing Crohn's disease with infliximab alone or as an adjunct to exam under anesthesia with seton placement. Inflamm Bowel Dis 2003;9:98-103.
31. Bell SJ, Halligan S, Windsor AC, Williams AB, Wiesel P, Kamm MA. Response of fistulating Crohn's disease to infliximab treatment assessed by magnetic resonance imaging. Aliment Pharmacol Ther 2003;17:387-93.
32. Levy C, Tremaine WJ. Management of internal fistuals in Crohn's disease. Inflamm Bowel Dis 2002;8:106-11.
33. Rutgeerts P, Feagan BG, Lichtenstein GR, et al. Comparison of scheduled and episodic treatment strategies of infliximab in Crohn's disease. Gastroenterology 2004;126:402-13.
34. Baert F, Noman M, Vermeire S, et al. Influence of immunogenicity on the long-term efficacy of infliximab in Crohn's disease. N Engl J Med 2003;348:601-8.
35. Cuffari C, Lichtenstein GR. Maintenance infliximab therapy in patients with Crohn's disease: How long, how much, how frequent? Gastroenterology 2003;124:1988-90.
36. Cornillie F, Shealy D, D'Haens G, et al. Infliximab induces potent anti-inflammatory and local immunomodulatory activity but no systemic immune suppression in patients with Crohn's disease. Aliment Pharmacol Ther 2001;15:463-73.
37. Garcia-Planella E, Domenech E, Esteve-Comas M, et al. Development of antinuclear antibodies and its clinical impact in patients with Crohn's disease treated with chimeric monoclonal anti-TNF alpha antibodies (infliximab). Eur J Gastroenterol Hepatol 2003;15:351-4.
38. Arnott ID, McNeill G, Satsangi J. An analysis of factors influencing short-term and sustained response to infliximab treatment for Crohn's disease. Aliment Pharmacol Ther 2003;17:1451-7.
39. Parsi MA, Achkar JP, Richardson S, et al. Predictors of response to infliximab in patients with Crohn's disease. Gastroenterology 2002;123:707-13.
40. Sandborn WJ. Preventing antibodies to infliximab in patients with Crohn's disease: Optimize not immunize. Gastroenterology 2003;124:1140-5.
41. Kugathasan S, Levy MB, Saeian K, et al. Infliximab retreatment in adults and children with Crohn's disease: Risk factors for the development of delayed severe systemic reaction. Am J Gastroenterol 2002;97:1408-14.
42. Nikolaus S, Raedler A, Kuhbacker T, Sfikas N, Folsch UR, Schreiber S. Mechanisms in failure of infliximab for Crohn's disease. Lancet 2000;356:1475-9.
43. Kinney T, Rawlins M, Kozarek R, France R, Patterson D. Immunomodulators and "on demand" therapy with infliximab in Crohn's disease: Clinical experience with 400 infusions. Am J Gastroenterol 2003;98:608-12.
44. Farrell RJ, Alsahli M, Jeen YT, Falchuk KR, Peppercorn MA, Michetti P. Intravenous hydrocortisone premedication reduces antibodies to infliximab in Crohn's disease: A randomized controlled trial. Gastroenterology 2003;124:917-24.
45. Massironi S, Losco A, Basilisco G. Drug side-effects in IBD. Aliment Pharmacol Ther 2002;16:1831.
46. von Haehling S, Jankowska EA, Anker SD. Tumour necrosis factor-alpha and the failing heart - pathophysiology and therapeutic implications. Basic Res Cardiol 2004;99:18-28.
47. Chung ES, Packer M, Lo KH, Fasanmade AA, Willerson JT. Randomized, double-blind, placebo-controlled, pilot trial of infliximab, a chimeric monoclonal antibody to tumor necrosis factor-alpha, in patients with moderate-to-severe heart failure: Results of the anti-TNF Therapy Against Congestive Heart Failure (ATTACH) trial. Circulation 2003;107:3133-40.
48. Kwon HJ, Cote TR, Cuffe MS, Kramer JM, Braun MM. Case reports of heart failure after therapy with a tumor necrosis factor antagonist. Ann Intern Med 2003;138:807-11.
49. Wallis RS, Broder MS, Wong JY, Hanson ME, Beenhouwer DO. Granulomatous infectious diseases associated with tumor necrosis factor antagonists. Clin Infect Dis 2004;38:1261-5.
50. Ricart E, Panaccione R, Loftus EV, Tremaine WJ, Sandborn WJ. Successful management of Crohn's disease of the ileoanal pouch with infliximab. Gastroenterology 1999;117:429-32.
51. Martinez F, Nos P, Benlloch S, Ponce J. Hidradenitis suppurativa and Crohn's disease: Response to treatment with infliximab. Inflamm Bowel Dis 2001;7:323-6.
52. Papadakis KA, Treyzon L, Abreu MT, Fleshner PR, Targan SR, Vasiliauskas EA. Infliximab in the treatment of medically refractory indeterminate colitis. Aliment Pharmacol Ther 2003;18:741-7.
53. Regueiro M, Valentine J, Plevy S, Fleisher MR, Lichtenstein GR. Infliximab for treatment of pyoderma gangrenosum associated with inflammatory bowel disease. Am J Gastroenterol 2003;98:1821-6.
54. Viscido A, Habib FI, Kohn A, et al. Infliximab in refractory pouchitis complicated by fistulae following ileo-anal pouch for ulcerative colitis. Aliment Pharmacol Ther 2003;17:1263-71.
55. Markowitz J, Grancher K, Kohn N, Lesser M, Daum F. A multicenter trial of 6-mercaptopurine and prednisone in children with newly diagnosed Crohn's disease. Gastroenterology 2000;119:895-902.
56. Puchner TC, Kugathasan S, Kelly KJ, Binion DG. Successful desensitization and therapeutic use of infliximab in adult and pediatric Crohn's disease patients with prior anaphytactic reaction. Inflamm Bowel Dis 2001;7:34-7.
57. Persley KM. Infliximab infusion reactions: Desensitizing ourselves to the danger. Inflamm Bowel Dis 2004;10:62-3.
58. Cheifetz A, Smedley M, Martin S, Reiter M, Leone G, Mayer L. The incidence and management of infusion reactions to infliximab: A large center experience. Am J Gastroenterol 2003;98:1315-24.
59. Crandall WV, Mackner LM. Infusion reactions to infliximab in children and adolescents: Frequency, outcome and a predictive model. Aliment Pharmacol Ther 2003;17:75-84.
60. Sandborn WJ, Hanauer SB. Infliximab in the treatment of Crohn's disease: A user's guide for clinicians. Am J Gastroenterol 2002;97:2962-72.